162536-84-7

Usage

Uses

Used in Organic Synthesis:
ERYTHRO-N-BOC-O-BENZYL-L-TYROSINE EPOXIDE is used as a building block for the creation of complex organic molecules. Its unique structure and reactive epoxide group facilitate the synthesis of new compounds with tailored properties, making it a versatile component in the development of advanced materials and pharmaceuticals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, ERYTHRO-N-BOC-O-BENZYL-L-TYROSINE EPOXIDE is used as a precursor in the development of new drugs. Its ability to target specific cellular pathways or biochemical processes positions it as a promising candidate for the treatment of various diseases and conditions. ERYTHRO-N-BOC-O-BENZYL-L-TYROSINE EPOXIDE's enhanced solubility and reactivity also contribute to its potential as a therapeutic agent.
Used in Drug Development:
ERYTHRO-N-BOC-O-BENZYL-L-TYROSINE EPOXIDE is utilized as a key intermediate in the synthesis of innovative drug molecules. Its unique chemical properties allow for the design of drugs with improved efficacy, selectivity, and reduced side effects. ERYTHRO-N-BOC-O-BENZYL-L-TYROSINE EPOXIDE's potential as a drug candidate is further supported by its ability to modulate specific biological targets, offering new avenues for therapeutic intervention in various medical fields.

Upstream product

• 152438-62-5 (S)-N-[3-Chloro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]carbamic acid 1,1-dimethylethyl ester 
• 127132-32-5 ethyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-O-(phenylmethyl)-L-tyrosinate 
• 174801-33-3 (2S,3S)-N-tert-butoxycarbonyl-3-amino-4-(4-benzyloxyphenyl)-1-chloro-2-hydroxybutane 

Downstream Products

• 162536-85-8 (2S,3S)-N-tert-butoxycarbonyl-3-amino-1,2-epoxy-4-(4-hydroxyphenyl)butane 
• 313680-04-5 (3R,3AS,6AR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}benzyl)-2-hydroxypropylcarbamate 
• 313680-02-3 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-(4-{3-[(tert-butoxycarbonyl)amino]propoxy}benzyl)-2-hydroxypropylcarbamate 
• 313680-00-1 (3R,3AS,6AR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-(4-{2-[(tert-butoxycarbonyl)amino]ethoxy}benzyl)-2-hydroxypropylcarbamate 
• 313680-05-6 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-1-[4-(4-aminobutoxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl) amino]-2-hydroxypropylcarbamate 
• 313680-03-4 (3R,3AS,6AR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-1-[4-(3-aminopropoxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxypropylcarbamate 

Relevant academic research and scientific papers

Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles

A novel series of tyrosine-derived HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and two protease inhibitor-resistant viruses. All of the compounds had wild-type antiviral activities that were similar to or greater than several currently marketed HIV protease inhibitors. In addition, a number of compounds in this series were more potent against the drug-resistant mutant viruses than they were against wild-type virus.